A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
1060 patients around the world
Available in Argentina, Brazil, United States
Novo Nordisk A/S
9Research sites
1060Patients around the world
This study is for people with
Diabetes
Diabetes mellitus type 2
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Male or female (sex assigned at birth, inclusive of all gender identities).
Age 18 years or above at the time of signing the informed consent.
Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥ )180 days before screening.
On stable daily dose(s) of metformin, SGLT2 (sodium-glucose cotransporter 2) inhibitor, or both (at effective or maximum tolerated dose as judged by the investigator) prior to screening.
Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening.
Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening.
Planned coronary, carotid or peripheral artery revascularisation.
Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria before screening. However, insulin treatment for gestational diabetes is allowed as well as short term insulin treatment for a maximum of 14 consecutive days. However, insulin treatment for gestational diabetes or short-term insulin treatment for a maximum of 14 consecutive days is allowed.
Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.
Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.
Sites
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Viamonte 2213, C1056ABI Cdad. Autónoma de Buenos Aires, Argentina
Instituto de Investigaciones Clínicas (IIC) - Rosario
Paraguay 160, S2000CVD Rosario, Santa Fe, Argentina
Centro Médico Privado San Vicente Diabetes - Córdoba
Entre Ríos 2977, Córdoba
Fundación Centro de Salud e Investigaciones Médicas (CESIM)
Urquiza 646, Santa Rosa, La Pampa
CPQuali Pesquisa Clínica
Avenida Angélica, 916 Conjunto 506 - São Paulo 01228-000
BR Trials - Pesquisa Clínica - Sao Paulo
Av. Arnolfo Azevedo, 40 - Pacaembu, São Paulo - SP, 01236-030, Brazil